Experimental studies suggest that the renin-angiotensin system (RAS) and its primary effector peptide, angiotensin II (Ang II), are involved in the pathophysiology of cardiac hypertrophy and failure. All the components required for Ang II production are present in the heart, and cardiac Ang II formation appears to be regulated independent from the circulating RAS. In animal models and in patients with heart failure, the cardiac RAS is activated and, presumably, local Ang II formation is enhanced. Several cardiac cell types express Ang II type 1 (AT ) and / or type 2 (AT )-receptors and represent potential targets for Ang II-mediated effects. In neonatal cardiac myocytes, Ang signaling cascades potently modulate cardiac myocyte function and growth. However, studies in AT -receptor knockout mice demonstrate 1 that cardiac hypertrophy in response to hemodynamic overload can occur independent from the AT -receptor. In this paper, we review 1 recent experimental evidence suggesting a critical role for the RAS in cardiac hypertrophy and failure with special emphasis on the putative role of Ang II and Ang II-receptor signaling in cardiac myocytes.
differentiated cardiac myocytes and in perfused heart preparations. In the neonatal system, Ang II appears to be a major autocrine / paracrine mediator of cardiac myocyte hypertrophy in response to passive mechanical stretch. By contrast, AT -receptor activation the heart and prolongs long-term survival in animal models of cardiac hypertrophy and failure. The therapeutic effects of ACE inhibitors and AT -receptor antagonists clearly suggest an important role for the ACE-Ang II-AT -receptor axis in the development of cardiac 1 1 hypertrophy and failure. It must be kept in mind, however, that these drugs enhance AT -receptor and B -kinin receptor-dependent 2 2 signaling pathways which may contribute significantly to the beneficial effects observed in vivo. Molecular and physiological analyses of transgenic mice with a cardiac-specific overexpression of the AT or AT -receptor confirm that AT and AT -receptor-dependent 1 2 1 2 signaling cascades potently modulate cardiac myocyte function and growth. However, studies in AT -receptor knockout mice demonstrate 1 1. Introduction dysfunction and impaired survival [1] . Considerable research efforts have focussed on the molecular mechanisms Cardiac hypertrophy is an important compensatory that transduce hemodynamic load into myocardial growth, mechanism of the heart in response to chronic increases in and that may be responsible for the transition to terminal hemodynamic load. Although myocardial hypertrophy heart failure. In this context, experimental studies in cell initially allows to maintain cardiac function, sustained culture systems, animal models and in patients indicate hemodynamic overloading eventually causes a transition that the RAS and its primary effector peptide, Ang II, are from compensatory hypertrophy to heart failure, characterinvolved in the pathophysiology of cardiac hypertrophy ized by chamber dilatation, progressive contractile and failure. The Ang II hypothesis is based on four main observations: (1) Ang II is produced locally within the myocardium, (2) the RAS is activated in the hypertrophied and failing heart, (3) Ang II potently modulates cardiac low, renin activity is readily detectable in the heart [5] . myocyte growth in vitro, and (4) pharmacological blocStudies in nephrectomized pigs have revealed that most, if kade of the RAS is highly effective in animal models and not all, renin in the heart is derived from the kidney, and in patients with cardiac hypertrophy and failure.
actively taken up from the circulation [6] . Renin-uptake has also been demonstrated in normal and failing human hearts [7] . It has been postulated that renin-uptake is 2. Ang II-producing pathways in the normal, mediated by binding of circulating renin to cell membranes hypertrophied and failing myocardium in the heart, possibly via an interaction with renin-binding proteins [7] [8] [9] . In patients with end-stage heart failure Traditionally, the RAS has been viewed solely as a receiving ACE-inhibitor therapy and displaying increased circulating system involved in the regulation of blood circulating levels of renin, cardiac renin concentration is pressure and salt and fluid homeostasis [2] . According to increased as well and directly correlated with plasma renin this concept, the kidney releases renin and its inactive levels, suggesting enhanced uptake from the circulation precursor prorenin into the circulation. Liver-derived an- [7] . Interestingly, cardiac angiotensinogen levels in these giotensinogen is then cleaved by renin in the circulating patients are reduced and are inversely correlated with blood to form Ang I. ACE, located on the luminal side of cardiac renin levels, suggesting enhanced cleavage of the vascular endothelium, finally converts Ang I to the angiotensinogen and an increased local production of Ang biologically active octapeptide Ang II, which promotes I in the failing human heart [7] . Increased expression of vasoconstriction and aldosterone release (Fig. 1 ). This renin mRNA has been detected in the borderzone of the classic concept has undergone important changes, because infarcted left ventricle in rats, indicating that cardiac renin accumulating evidence indicates that the components of expression may be induced under pathological conditions the RAS are synthesized in many tissues, and that tissue [10] . Ang II levels can be controlled independent from the In contrast to renin, angiotensinogen appears to be circulating RAS. In fact, renin, angiotensinogen, ACE and synthesized locally within the myocardium [11] [12] [13] [14] . Under angiotensin receptors are present in the heart, suggesting physiological conditions, however, cardiac angiotenthat Ang II synthesized locally within the myocardium sinogen expression levels are rather low, as indicated by may be an autocrine / paracrine modulator of cardiac experiments in isolated perfused rat hearts which demonfunction and structure [3, 4] .
strate that the heart produces little Ang I unless renin and Although cardiac renin mRNA expression is extremely angiotensionogen are added to the perfusion fluid [15] . However, in rats with chronic pressure overload and in rats employed is this study has been criticized, as it may have with left ventricular failure early after coronary artery led to a loss of chymase activity [29, 31] . Chymase-like ligation or following tachypacing, cardiac angiotensinogen immunoreactivity is found primarily in the extracellular gene expression is enhanced, suggesting that the local matrix of the heart, with cardiac mast cells, endothelial generation of angiotensinogen within the myocardium may cells and mesenchymal interstitial cells being the prebecome more important during cardiac hypertrophy and dominant cellular sites of chymase synthesis and storage failure [11, 13, 16] . [32] . It is believed that chymase must be actively secreted Many studies have indicated that the angiotensin-conby these cell types, before chymase-mediated conversion verting enzyme is present within the myocardium. In the of Ang I can take place [32] . Therefore, studies using normal heart of rats and humans, ACE expression is cardiac membrane preparations may overestimate confined almost exclusively to the endothelial cells of chymase-driven Ang I conversion, because chymase-concoronary arteries, arterioles and capillaries [17] . Myocartaining mast cell granules are disrupted during tissue dial expression of ACE is increased in rats with pressure preparation. In fact, in the intact human heart, ACE has overload ventricular hypertrophy and in the viable myocarbeen shown to be the predominant Ang II-forming endium following experimental myocardial infarction [18-zyme, at least across the coronary circulation [30] . More-21]. Moreover, ACE has been shown to be upregulated in over, protease inhibitors (e.g. a -antitrypsin) present in the 1 the myocardium of patients with end-stage heart failure, interstitial fluid potently inhibit chymase activity, and it regardless of the etiology, i.e. in patients with ischemic as has therefore been postulated that, also in the cardiac well as with idiopathic dilated cardiomyopathy [22] . In the interstitium, Ang II formation may primarily be regulated hypertrophied or failing ventricle, endothelial cells conby ACE rather than chymase [31] . Clearly, more research tinue to be a major site of cardiac ACE expression, but is needed to elucidate the pathophysiological triggers that ACE expression becomes detectable in other cell types as may cause cardiac mast cell activation and chymase well [17, [23] [24] [25] . For example, after coronary artery ligarelease in vivo. In this regard, a recent study has demontion in rats, ACE is markedly increased within the infarct strated that myocardial ischemia represents a potent scar and in areas of fibrous tissue formation remote from stimulus for mast cell degranulation [33] . With regard to the site of infarction [23] . Likewise, increased ACE the failing human heart, there appears to be no induction of activity has been detected in left ventricular aneurysms of chymase mRNA or enzyme activity as compared to patients after myocardial infarction [24] . A report from the nonfailing hearts [22, 32] . same group indicated that ACE was expressed in fibroIn summary, all the components required for Ang II blasts, macrophages and endothelial cells present in the production are present in the heart. In fact, it has been scar tissue and in cardiac myocytes in the region adjacent shown that most Ang I found in cardiac tissue is synto the infarct scar [25] .
thesized in situ, and that most of the cardiac Ang II is Only a few studies have addressed the critical question, produced by the conversion of locally produced, rather whether enhanced cardiac expression of ACE actually than blood-derived, Ang I [34] . More importantly, there is promotes an increased production of Ang II. By using now convincing evidence that the cardiac RAS is capable isolated, perfused hearts from normal rats and rats with of regulating Ang II levels locally within the myocardium, pressure overload hypertrophy, Schunkert and co-workers independent from systemic Ang II generation [35, 36] . It is [18, 26] demonstrated that the upregulation of ACE in the therefore critical to identify the cells types in the myocarhypertrophied left ventricle is associated with an increased dium that actually express Ang II receptors and represent intracardiac conversion of Ang I to Ang II.
potential targets for Ang II-mediated effects. Several groups have challenged the notion that ACE Ang II receptors belong to the large family of seven represents the major Ang II-forming enzyme in the human transmembrane receptors, and have been divided into two heart. Urata and co-workers [27, 28] demonstrated that pharmacologically distinct types, designated type 1 (AT ) 1 ACE-inhibitors could block only 10-20% of total Ang I to and type 2 (AT ) [37, 38] . In rodents, two AT -receptor 2 1 Ang II conversion in left ventricular membranes prepared subtypes, designated AT and AT , have been identified.
1A 1B
from human hearts. The remaining activity was blocked by The AT and AT -receptor subtypes are encoded by 1A 1B a serine protease inhibitor, pointing to chymase as an distinct genes, but share a 96% homology at the amino ACE-bypassing enzyme. In agreement with these early acid level [39] . Due to the lack of discriminatory pharmadata, Wolny et al. [29] , employing a similar method to cological antagonists, distinct functions of the two AT -1 prepare cardiac membranes, concluded that a chymase-like receptor subtypes have not been defined. On the mRNA enzyme is the major Ang I-converting activity in human level, the AT -receptor subtype is much more abundant 1A hearts. In contrast with these results, Zisman et al. [30] than the AT -receptor subtype in most tissues, including 1B reported that the ACE-inhibitor enalapril could inhibit 85% the heart [40, 41] . Radiolabeled Ang II-binding assays have of Ang I-conversion in solubilized human cardiac memsuggested, that both AT -and AT -receptors are present in accounting for about 50-70% of specific Ang II binding tion sequences in the promotor region of the AT -re-1A ceptor are involved in the load-dependent regulation of [42] [43] [44] . Ang II-binding assays in isolated cardiomyocytes AT -receptor expression in rat cardiac myocytes in vivo and in cardiac fibroblasts from adult rat heart indicate that 1A [53] . both cell types express the AT -receptor exclusively Several groups have investigated Ang II receptor regula-47]. AT -receptor density on rat cardiac myocytes appears 1 tion in human heart failure [51, [54] [55] [56] . By using standardto be rather low, however, and some authors have failed to calibrated RT-PCR analysis, Haywood et al. [56] demondetect Ang II receptors in isolated cardiomyocytes from strated that AT -receptor mRNA expression is reduced, normal rat hearts [48] . AT -receptor expression in the 1 2 whereas AT -receptor mRNA expression is unchanged in myocardium and in coronary vessels has recently been 2 failing human hearts. A similar conclusion was reached by confirmed by immunohistochemistry [49] , and reverse Asano et al. [55] , who analysed the binding of radiolabeled transcription polymerase chain reaction [41] . AT -receptor 2 Ang II to cardiac membranes prepared from terminally expressing cell types in the heart remain poorly characterfailing and control hearts: in the failing heart, AT -receptor ized, however, but may include coronary endothelial cells 1 density was downregulated, whereas AT -receptor density [49] and, as suggested by some authors, cardiac fibroblasts 2 was unaltered. Moreover, in situ RT-PCR in sections of [50, 51] . Several studies, however, have questioned whether failing and nonfailing ventricles indicated that AT -rethere is any significant AT -receptor expression in adult rat
ceptor mRNA was present in both myocytes and the heart. In fact, in situ hybridization and sensitive poly(A) -interstitium [55] . It should be noted however, that the total Northern blot analyses failed to identify AT -receptor 2 number of Ang II binding sites in the human ventricle mRNA expression in adult rat myocardium, whereas AT -1 appears to be quite low, i.e. only approximately 10% of the receptor mRNA was readily detectable [37, 38, 52] . The total number of b-adrenergic binding sites [55] . In contrast discordant results with regard to AT -receptor expression 2 to these previous studies [55, 56] , Tsutsumi et al. [51] in adult heart make it difficult to obtain a coherent picture recently reported that AT -receptor binding sites and at the present time [52] . 2 mRNA expression are increased in patients with dilated A number of studies indicate that Ang II receptor cardiomyopathy. Interestingly, the enhanced expression of expression in the heart is altered in animal models of the AT -receptor was associated with a substantial increase ventricular hypertrophy and failure. Suzuki et al. [43] 2 in the expression levels of extracellular matrix genes, and demonstrated that left ventricular AT and AT -receptor 1 2 cardiac fibroblasts in the interstitial space were found to be densities and AT -receptor mRNA levels are increased in 1A the major AT -receptor expressing cell type in the failing rats with renovascular or spontaneous hypertension. Rats 2 hearts [51] . It is not known whether the changes in with cardiac hypertrophy due to aortic banding, however, receptor density contribute to, or compensate for the exhibit a decrease in total cardiac Ang II binding sites deterioration in human heart failure or whether they simply associated with a receptor subtype redistribution, i.e. a represent an epiphenomenon. Moreover, it remains to be shift towards a preponderance of the AT -receptor [44] . 2 determined whether the changes in receptor subtype denEmploying RT-PCR analyses, Nio et al. [41] reported that sity in the failing heart result in an altered response to Ang AT and AT -receptor mRNA expression is upregulated 1A 2 II. Conceivably, downregulation of the AT -receptor in in the infarcted and noninfarcted portions of the left 1 human heart failure may result in an increase in available ventricle following coronary ligation in the rat. UnforAng II levels, and AT -receptor-mediated effects may tunately, the cell types expressing AT and AT -receptors 2 1 2 become more evident [57] . were not identified in that study. In this regard, Meggs et Ang II has long been recognized as the major inducer of al. [45] demonstrated that cardiac myocytes isolated from aldosterone synthesis in the adrenal glands. More recent rats with post-infarction left ventricular failure exhibit an data indicate that aldosterone may also be formed locally increase in AT -receptor density, which may be associated 1 within the heart, and that cardiac aldosterone synthesis is with an enhanced susceptibility to Ang II in vitro. In the 1 enhanced by Ang II [58] . By causing Na absorption as same study it was shown that hypertrophied myocytes, like 1 21 myocytes from control hearts, do not express AT -receptor well as K and Mg excretion in the kidneys, aldosterone 2 binding sites [45] . In apparent contrast to the infarct promotes water retention and contributes to electrical model, cardiac AT and AT -receptor mRNA expresinstability in heart failure. In addition, aldosterone has 1A 1B sion is unchanged in rats with aortocaval shunt and left been shown to modulate the phenotype of cardiac fiventricular failure [14] . The pathophysiological mechabroblasts and, potentially, cardiac myocytes through an nisms underlying the distinct patterns of AT and ATinteraction with the mineralocorticoid receptor in these cell 1 2 receptor regulation in different animal models are largely types [59, 60] . In cultured cardiac fibroblasts, aldosterone unknown. Certainly, we need a better understanding of the promotes type I collagen mRNA and protein synthesis molecular mechanisms controlling Ang II receptor abun- [59] . In neonatal cardiac myocytes, aldosterone stimulates dance in different cardiac cell types. In this regard, it has protein accumulation, suggesting a hypertrophic effect been suggested that the AP-1 and GATA-4 DNA-recogni- [60] . The pathophysiological significance of aldosterone in heart failure is highlighted by the results of the recent factors STAT1, STAT2 and STAT5 in neonatal carRandomized Aldactone Evaluation Study (RALES). In this diomyocytes [74, 75] . It remains largely unknown how study, treatment with an aldosterone antagonist on top of these distinct signaling pathways promote the molecular ACE inhibitors and loop diuretics, significantly reduced all and morphological features of the hypertrophic response. cause mortality in patients with symptomatic heart failure In this regard, activation of phospholipases and PKC [61] .
appears to play an essential role in the Ang II-mediated induction of c-fos [69] , whereas 70-kDa S6 kinase seems to be required for Ang II-enhanced protein accumulation 3. Ang II and load-induced phenotype changes in [76] . More recently, activation of the small G-protein, cardiac myocytes
RhoA, has been shown to be involved in myofibril formation by Ang II [77] , and reactive oxygen species Our current knowledge regarding the signal transduction were found to be critical for Ang II-induced protein pathways and the biological effects of Ang II in cardiac accumulation in neonatal cardiomyocytes [78] . myocytes has primarily been obtained from a cell culture It has been questioned whether the effects of Ang II in model employing ventricular cardiac myocytes from neonatal cardiomyocyte culture are mediated via a direct neonatal rats. Both AT -and AT -receptor are expressed interaction of Ang II with the AT -receptor on neonatal [62, 63] .
ANP production and cell size in highly purified neonatal Stimulation of neonatal cardiomyocytes with Ang II cardiomyocytes. However, upon inclusion of even a small induces the transcription of proto-oncogenes (such as c-fos, percentage (5%) of nonmyocytes (mostly fibroblasts) in the c-jun, c-myc and Egr-1), the reactivation of a fetal culture system, Ang II readily induced cardiomyocyte program of cardiac gene expression (i.e. the induction of hypertrophy. In the same study [80] , Ang II induced ANP, skeletal a-actin, and b-myosin heavy chain), an endothelin-1 secretion from nonmyocytes, and the hyenhanced synthesis of growth factors, including plateletpertrophic effect of Ang II in myocyte-nonmyocyte derived growth factor and transforming growth factor-b, cocultures was partially blocked by an ET-A receptor
and a decreased expression of the Na / Ca -exchanger antagonist. The hypertrophic effects of Ang II in neonatal 21 and sarcoplasmic reticulum Ca -ATPase [64, 65] . Morecardiomyocytes may therefore depend, at least in part, on over, Ang II enhances total protein accumulation, promotes the release of endothelin-1 and additional as yet unknown the formation of new myofibrils, and induces an increase in paracrine factors from nonmyocytes present in the cell cell size. Apparently, all of these effects are mediated by culture system. the AT -receptor [64] . More recent studies have indicated Neonatal cardiac myocytes have also been used as a cell 1 that the effects of Ang II on protein accumulation are culture model to study the mechanisms whereby external potentiated in the presence of selective AT -receptor load is converted into intracellular growth signals (re-diomyocytes from angiotensinogen and AT -receptor tions, support the conclusion that load-induced hyper-1A knockout mice have revealed that Ang II-AT -receptor trophy in adult cardiac myocytes can occur independent 1 signaling is dispensable for the stretch-induced activation from the AT -receptor. In this model, Ang II as well as 1 of ERKs [92, 93] . In line with these observations, acute increases in systolic wall stress promote a marked endothelin-1 been shown to be released from neonatal stimulation of total protein synthesis [107, 108] . The hycardiomyocytes in response to mechanical stretch and to pertrophic response to Ang II is completely abolished by promote hypertrophy in synergy with Ang II, and cyto-AT -receptor blockade, indicating that the AT -receptor 1 1 kines signaling through the gp130-receptor have been mediates the trophic effects of Ang II [108] . By contrast, implicated in the stretch-induced activation of ERKs AT -receptor antagonism does not prevent the growth 1 1 1 [94, 95] . Finally, activation of the Na / H -exchanger by response to acute pressure overload [109] . Interestingly, Ang II-dependent and Ang II-independent pathways has the increase in protein synthesis in response to Ang II is recently been shown to play a critical role in stretchblunted in hypertrophied hearts from rats with ascending induced hypertrophy of neonatal cardiomyocytes [96, 97] .
aortic stenosis [107] . Earlier studies have demonstrated Several studies have examined the effects of Ang II on that a redistribution of angiotensin receptor subtypes isolated, terminally differentiated adult cardiomyocytes.
occurs in these hearts, resulting in a preponderance of the Ang II-stimulation of adult ventricular cardiomyocytes AT -receptor [44] . Intriguingly, perfusion of hypertrophied 2 isolated from rabbit or rat has been shown to stimulate hearts with Ang II and a specific AT -receptor antagonist 2 
1
Na / H -exchange, resulting in an intracellular alkalinizarestores the growth promoting effects of Ang II, indicating tion and an increase in the amplitude of cell contraction that the upregulation of the AT -receptor in pressure 2 1 1 [98, 99] . Remarkably, Ang II does not increase Na / Hoverload hypertrophy blunts the growth response to Ang II exchange and cell contraction amplitude in hypertrophied [110] . myocytes isolated from rats following aortic banding [99] .
A report from Anversa's group [111] has demonstrated In contrast to these results, that suggest a positive inotropic that mechanical stretch promotes Ang II release and effect of Ang II, at least on nonfailing, rodent carapoptosis in adult rat cardiac myocytes in vitro, and that diomyocytes, other investigators have not been able to AT -receptor blockade prevents apoptosis in this setting, 1 detect any significant effects of Ang II on the contraction suggesting a critical role for Ang II. Indeed, in a study characteristics of adult cardiomyocytes from normal guinea from the same lab, Ang II was shown to induce apoptosis pig or rat hearts [100] . The reason(s) for these discrepant in cultured adult rat cardiac myocytes via the AT -receptor 1 results are not clear. With regard to the human heart, Ang [112] . It has been postulated that ongoing cardiomyocyte II does not appear to promote a direct positive inotropic dropout by apoptosis contributes to the progression of effect on isolated cardiac myocytes and muscle-strip compensatory cardiac hypertrophy to overt heart failure, preparations from human left ventricle [100, 101] .
and that an increase in ventricular wall stress represents a Mechanical stretch has been shown to enhance gene potential trigger mechanism for apoptosis in the heart expression and protein accumulation in isolated adult [113] . Therefore, the observation that Ang II can mediate ventricular cardiomyocytes, indicating that an increase in stretch-induced cardiac myocyte apoptosis may be of external load is a sufficient stimulus for the activation of a clinical relevance. hypertrophic response in adult cardiomyocytes, as well [102, 103] . Although prolonged stimulation of adult cardiac myocytes with Ang II promotes a modest increase in 4. ACE-inhibitors and AT -receptor antagonists in 1 protein synthesis via the AT -receptor [104, 105] , the experimental heart failure 1 increase in protein synthesis in response to mechanical stretch appears to be mediated by Ang II-independent ACE inhibitors favorably alter hemodynamics, improve mechanisms [103] . Interestingly however, stretch-induced symptoms and reduce overall mortality in patients with expression of the protooncogene c-fos can be blocked by a congestive heart failure (reviewed in Ref.
[114]). A recent competitive peptide to Ang II, indicating a requirement for clinical trial suggests that AT -receptor antagonists reduce 1 Ang II at least for this early response to passive load [103] . mortality in heart failure patients as well [115] . The In a recent study, Ang II was shown to induce the therapeutic efficacy of ACE inhibition and AT -receptor 1 expression of the MAPK-phosphatase MKP-1 through the blockade has been viewed as strong evidence for a critical AT -receptor in adult cardiac myocytes [106] . Although involvement of the RAS in the pathophysiology of conges-2 this observation appears to contradict earlier reports that tive heart failure. However, ACE inhibitors and AT -1 failed to detect significant AT -receptor expression in receptor antagonists promote important biological effects 2 cultured adult rat cardiomyocytes [45, 47] , it raises the beyond the inhibition of Ang II formation or the interferintriguing possibility that Ang II may promote growthence with Ang II at the AT -receptor level (Fig. 1) . ACE 1 inhibiting effects in cardiac myocytes via AT -receptor acts as a potent kinin-degrading enzyme, and, accordingly, 2 stimulation [106] . plasma and tissue kinin levels are increased by ACE Studies in isovolumic perfused beating rat heart preparainhibitors [116] [117] [118] . During AT -receptor blockade, plas-ma Ang II levels increase which may promote an enhanced considered as well. During chronic ACE inhibition, plasma activation of the AT -receptor [119] . Importantly, in renin increases and promotes enhanced Ang I formation 2 certain cell types, activation of the AT -receptor triggers from angiotensinogen [118, 128] . When ACE is inhibited 2 kinin generation and nitric oxide production, suggesting and Ang I is increased, conversion of Ang I to the that AT -receptor antagonists may enhance kinin-mediated bioactive peptide Ang-(1-7) by enzymatic reactions dis-1 effects [120] . Therefore, the therapeutic effects of ACE tinct from ACE may become more significant [129, 130] . In inhibitors and AT -receptor antagonists may not be depend addition, a decreased metabolism of Ang-(1-7) appears to 1 solely on the interference with the ACE-Ang II-ATcontribute to the increase in Ang-(1-7) levels during 1 receptor pathway, but may also relate to kinin potentiation ACE-inhibition because ACE degrades Ang-(1-7) to the and augmentation of AT -receptor-mediated effects. Iminactive fragment Ang-(1-5) [131] . Ang-(1-7), has been 2 portantly, depending on the animal model or the endpoint shown to activate the AT -receptor and / or putative non 2 studied, the mechanisms of action of ACE inhibitors and AT /AT angiotensin receptor(s) [132, 133] , and ac- 1 2 AT -receptor antagonists can differ significantly. The cumulating evidence suggests that Ang-(1-7) may oppose 1 following discussion focusses on two distinct rat models of the vasoconstrictor and growth-promoting actions of Ang cardiac hypertrophy / failure induced by myocardial infarc-II either directly or by stimulation of kinin, prostaglandin tion (MI) and ascending aortic stenosis.
and nitric oxide release (reviewed in Ref. [134] ). The As demonstrated in seminal studies from Pfeffer's group possibility that increased Ang-(1-7) levels and AT -re-2 [121, 122] , ligation of the left coronary artery in rats ceptor activation contribute to the antihypertrophic effects promotes profound alterations of ventricular architecture, of ACE inhibitors warrants further investigation. characterized by an early expansion of the infarcted area,
In the rat infarct model, AT -receptor antagonists are 1 hypertrophy of the surviving myocardium, progressive equally effective as compared to ACE inhibitors in reducdilatation of the left ventricle, and-depending on the size ing cardiomyocyte hypertrophy and long-term mortality of the infarct, frank cardiac failure. Soon thereafter, Pfeffer [135, 136] . Recent studies indicate that the inhibition of and co-workers [123, 124] realized that chronic ACE cardiomyocyte hypertrophy by AT -receptor blockade can 1 inhibition attenuates cardiac hypertrophy and chamber not be attributed solely to an inhibition of Ang II-AT -1 dilatation and improves long-term survival in the rat infarct receptor signaling [125, 126] . In fact, cotreatment with an model. Conceivably, the therapeutic effects of ACE in-AT -receptor antagonist abolishes the attenuation of car- . Therefore, unloading of the ventricle and / in this model [125, 126] . or inhibition of ACE within tissues appear to be critical for
The rat model of ascending aortic stenosis represents the beneficial effects of ACE inhibitors. As shown in another well characterized animal model of cardiac hyrecent studies, investigating combined ACE inhibition and pertrophy and failure. Clipping of the ascending aorta is B -kinin receptor blockade in the rat infarct model, kinins followed initially by a stage of compensated concentric left 2 appear to contribute to the reduction of interstitial myocarventricular hypertrophy. With time, however, ventricular dial fibrosis by ACE inhibitors [125, 126] . By contrast, the dilation and systolic dysfunction develop, and herald the attenuation of cardiomyocyte hypertrophy by ACE intransition to cardiac failure and premature death [137] . In hibitors is mediated by kinin-independent mechanisms, the early stage of compensated hypertrophy, left ventricusuggesting that this effect is related instead to a reduction lar ACE mRNA expression and activity are elevated and of Ang II formation [125] . In line with this conclusion, associated with an increased intracardiac generation of myocardial Ang II levels have been shown to be decreased Ang II [18, 26] . Chronic ACE inhibition reduces carsignificantly during chronic ACE inhibition in post MI rats diomyocyte hypertrophy, preserves contractile function, [125, 127] . However, alternative mechanisms need to be prevents the transition to failure and prolongs survival in Therefore, it will be critical to examine whether cardiac locally within the heart. In contrast to ACE inhibition, hypertrophy (e.g. in response to pressure overload) is chronic AT -receptor blockade does not reduce carblunted in aMHC-AT -receptor transgenic mice. 1 2 diomyocyte hypertrophy and long term mortality in rats Several groups have generated mice with a targeted with aortic stenosis [139] . These results suggest that: (1) disruption of the AT or AT -receptor genes to study the 1A 2 the beneficial effects of ACE inhibitors in this animal functional importance of the two major Ang II receptor model do not relate to a reduced formation of Ang II and types in the in vivo context [143] [144] [145] [146] . AT or AT - 1A 2 reduced AT -receptor activation, and that (2) AT -receptor receptor targeted mice are born according to Mendelian 1 1 independent pathways can promote cardiac hypertrophy in expectations and do not show any apparent histomorvivo -at least when the AT -receptor is blocked.
phological abnormalities of the heart, kidney or vascula- or loss-of-function mutations of specific components of the indispensible for the regulation of resting blood pressure RAS offer the unique opportunity to address the functional [143, 144] . By contrast, inactivation of the AT -receptor 2 significance of Ang II signaling in a defined genetic promotes hypertension, at least in some strain of mice background. In fact, physiological and molecular analyses [146] . Moreover, AT -deficient mice display an enhanced 2 of RAS-transgenic mice have allowed scientists to address pressure response to exogenous Ang II, indicating that the some of the most fundamental questions related to the AT -receptor normally serves to limit the pressure re-2 RAS and its putative role in cardiovascular pathophysiolsponse of the AT -receptor to Ang II [145, 146] . Finally, 1 ogy. The development of microsurgical techniques, and the AT -knockout mice show subtle behavioural disturbances, 2 adaptation of experimental models of cardiac hypertrophy including an impaired drinking response to water deprivaand failure to the mouse have been critical in this regard tion [145] , and an attenuated exploratory behaviour [146] . (reviewed in Ref. [140] ).
Harada and co-workers [147, 148] employed the AT -
1A
To elucidate whether Ang II can activate a growth receptor knockout mouse to analyse whether the AT -1A response in cardiac myocytes in vivo, independent from its receptor is required for the development of pressure hemodynamic effects, Hein et al. [141] have generated overload cardiac hypertrophy in vivo. Although expression mice overexpressing the AT -receptor under the control of the AT -receptor was detectable at very low levels in 1A 1B
of the cardiac myocyte-specific aMHC gene promotor. wild type and AT -receptor deficient hearts, infusions of 1A AT -transgenic mice exhibit a massive enlargement of subpressor doses of Ang II increased cardiac protoon-1A the atria due to hyperplasia of atrial myocytes, and die cogene expression and heart weight in wild type but not in shortly after birth, possibly related to bradycardia and heart AT -receptor deficient mice, indicating that the AT -1A 1B
block. As the murine aMHC gene promotor becomes receptor has no significant role in the promotion of cardiac activated in the ventricles only after birth, the effects of hypertrophy by exogenous Ang II [147, 148] . In sharp AT -overexpression in ventricular myocytes could not be contrast, acute pressure overload induced by transverse 1A assessed in this mouse model. However, the hyperplasia of aortic banding induced protooncogene expression and atrial myocytes in AT -transgenic mice strongly suggests MAPK activation in wild type as well as in AT -receptor 1A 1A
that Ang II can directly stimulate a growth response in targeted mice [148] . Moreover, chronic abdominal aortic cardiac myocytes via the AT -receptor [141] . In a recent banding induced cardiac hypertrophy in control mice as hood. AT -transgenic mice show a decreased sensitivity to downregulation of sarcoplasmic reticulum Ca -ATPase, angiotensin-converting enzyme after myocardial infarction. Hyperventricular fibrosis [147] . As shown by these elegant 
